Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Diaxonhit    ALEHT   FR0013240934

DIAXONHIT (ALEHT)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 11/23 11:24:51 am
4.78 EUR   --.--%
 SummaryQuotesChartsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
11/17/2017 11/20/2017 11/21/2017 11/22/2017 11/23/2017 Date
4.6(c) 4.61(c) 4.6(c) 4.78(c) 4.78 Last
7 033 5 198 10 126 16 272 20 915 Volume
-1.50% +0.22% -0.22% +3.91% 0.00% Change
More quotes
Financials (€)
Sales 2017 46,8 M
EBIT 2017 -4,00 M
Net income 2017 -5,40 M
Debt 2017 3,40 M
Yield 2017 -
Sales 2018 49,4 M
EBIT 2018 0,30 M
Net income 2018 -1,70 M
Debt 2018 2,40 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1,06x
EV / Sales2018 0,98x
Capitalization 46,1 M
More Financials
Company
Diaxonhit engages in the research and commercialization of diagnostic products.Its portfolio consists of proprietary diagnostic products in the following areas: transplantation, infectious diseases and cancer diagnosis.The company markets Tetanus Quick Stick used for the evaluation of patient's... 
More about the company
Latest news on DIAXONHIT

- No features available -

More news
Sector news : Biotechnology & Medical Research - NEC
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
More sector news : Biotechnology & Medical Research - NEC
Chart DIAXONHIT
Duration : Period :
Diaxonhit Technical Analysis Chart | ALEHT | FR0013240934 | 4-Traders
Technical analysis trends DIAXONHIT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 6,00 €
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Jean-Michel Carle Chairman-Management Board
Jean-Pierre Hermet Chairman-Supervisory Board
Hervé Duchesne de Lamotte Chief Financial Officer
Michel Picot Member-Supervisory Board
Danièle Guyot-Caparros Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
DIAXONHIT-22.90%54
CELLTRION, INC.--.--%24 331
IQVIA HOLDINGS INC37.23%21 966
INCYTE CORPORATION-1.32%20 893
LONZA GROUP62.21%19 860
ALNYLAM PHARMACEUTICALS, INC.252.59%13 012